CN102711785A - 预防或治疗心力衰竭的方法 - Google Patents

预防或治疗心力衰竭的方法 Download PDF

Info

Publication number
CN102711785A
CN102711785A CN2010800551907A CN201080055190A CN102711785A CN 102711785 A CN102711785 A CN 102711785A CN 2010800551907 A CN2010800551907 A CN 2010800551907A CN 201080055190 A CN201080055190 A CN 201080055190A CN 102711785 A CN102711785 A CN 102711785A
Authority
CN
China
Prior art keywords
arg
phe
lys
peptide
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800551907A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
彼得·S·拉宾诺维奇
戴道福
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Cornell University
Original Assignee
University of Washington
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Cornell University filed Critical University of Washington
Publication of CN102711785A publication Critical patent/CN102711785A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2010800551907A 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法 Pending CN102711785A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24868109P 2009-10-05 2009-10-05
US61/248,681 2009-10-05
US28948309P 2009-12-23 2009-12-23
US61/289,483 2009-12-23
PCT/US2010/051329 WO2011044044A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410049107.5A Division CN103845724A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Publications (1)

Publication Number Publication Date
CN102711785A true CN102711785A (zh) 2012-10-03

Family

ID=43823652

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800551907A Pending CN102711785A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法
CN201410049107.5A Pending CN103845724A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410049107.5A Pending CN103845724A (zh) 2009-10-05 2010-10-04 预防或治疗心力衰竭的方法

Country Status (7)

Country Link
US (7) US20110082084A1 (https=)
EP (5) EP2485749A4 (https=)
JP (6) JP2013506696A (https=)
CN (2) CN102711785A (https=)
CA (1) CA2776581C (https=)
HK (1) HK1217293A1 (https=)
WO (1) WO2011044044A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN112111003A (zh) * 2019-06-20 2020-12-22 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
US11771734B2 (en) 2013-03-01 2023-10-03 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth syndrome

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9306796B1 (en) 2008-03-18 2016-04-05 Mcafee, Inc. System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
JP6317324B2 (ja) * 2012-03-30 2018-04-25 ステルス ペプチドズ インターナショナル インコーポレイテッド 神経障害を予防および処置するための方法および組成物
AU2013334788A1 (en) * 2012-10-22 2015-06-04 Henry Ford Health Systems Methods for reducing risks associated with heart failure and factors associated therewith
CA2912386A1 (en) * 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
JP2016520130A (ja) * 2013-05-28 2016-07-11 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 心臓疾患における新規治療戦略としてのｂｅｔ阻害
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017861A1 (en) * 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2016004441A1 (en) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CA3010599C (en) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
WO2017151886A1 (en) * 2016-03-02 2017-09-08 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
US11865162B2 (en) 2016-07-01 2024-01-09 Marshall University Research Corporation Compositions and methods for treatment of uremic cardiomyopathy
CA3060985A1 (en) 2017-04-21 2018-10-25 Northeast Ohio Medical University Vasodilators for treatment of heart failure
WO2020118035A1 (en) * 2018-12-06 2020-06-11 Stealth Biotherapeutics Corp Methods and compositions for the treatment of sengers syndrome
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
US20230256047A1 (en) * 2020-06-17 2023-08-17 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
CA3191819A1 (en) 2020-09-09 2022-03-17 Hazel Szeto Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN117384253A (zh) * 2023-08-28 2024-01-12 南京医科大学 一类肽及其衍生物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
JP2002512954A (ja) * 1998-04-24 2002-05-08 マイトコー ミトコンドリア関連疾患を処置するための化合物および方法
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7855900A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
EP1303186B1 (en) * 2000-07-18 2011-01-26 Cornell Research Foundation, Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
IT1318370B1 (it) * 2000-12-21 2003-08-25 Tonino Bombardini Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7320959B2 (en) * 2001-10-01 2008-01-22 Vanderbilt University Use of calmodulin kinase II inhibitors to treat myocardial dysfunction in structural heart disease
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
JP4879020B2 (ja) * 2003-05-01 2012-02-15 コーネル リサーチ ファウンデイション インコーポレイテッド 細胞に分子を送達する方法及び担体複合体
US7232824B2 (en) * 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CA2947335A1 (en) * 2005-09-16 2007-03-29 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
DK2262520T3 (en) 2008-02-26 2017-08-07 Univ Cornell COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2485749A4 (en) 2009-10-05 2013-07-24 Univ Cornell METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
程龙献等: "降钙素基因相关肽的临床应用进展", 《医药导报》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339339A (zh) * 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
US11771734B2 (en) 2013-03-01 2023-10-03 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth syndrome
US12268724B2 (en) 2013-03-01 2025-04-08 Stealth Biotherapeutics Inc. Methods and compositions for the prevention or treatment of Barth Syndrome
CN112111003A (zh) * 2019-06-20 2020-12-22 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽

Also Published As

Publication number Publication date
JP2018203764A (ja) 2018-12-27
CA2776581C (en) 2020-12-15
EP3603658A1 (en) 2020-02-05
EP2485749A1 (en) 2012-08-15
JP2020097627A (ja) 2020-06-25
EP3120860A1 (en) 2017-01-25
JP7017762B2 (ja) 2022-02-09
JP2022046811A (ja) 2022-03-23
JP2013506696A (ja) 2013-02-28
US11534476B2 (en) 2022-12-27
EP3120860B1 (en) 2019-06-26
CN103845724A (zh) 2014-06-11
US20140100166A1 (en) 2014-04-10
CA2776581A1 (en) 2011-04-14
EP2485749A4 (en) 2013-07-24
JP7382607B2 (ja) 2023-11-17
US20210187056A1 (en) 2021-06-24
EP2764871A1 (en) 2014-08-13
US20230285499A1 (en) 2023-09-14
HK1217293A1 (en) 2017-01-06
EP3603658B1 (en) 2025-01-08
JP2015163609A (ja) 2015-09-10
JP6429835B2 (ja) 2018-11-28
US20110082084A1 (en) 2011-04-07
WO2011044044A1 (en) 2011-04-14
US20160106800A1 (en) 2016-04-21
US20200188470A1 (en) 2020-06-18
US12102659B2 (en) 2024-10-01
US20180236025A1 (en) 2018-08-23
JP2016190876A (ja) 2016-11-10
EP2944317A1 (en) 2015-11-18

Similar Documents

Publication Publication Date Title
US12102659B2 (en) Methods for the prevention or treatment of heart failure
US20250319152A1 (en) Methods for the prevention or treatment of left ventricle remodeling
CN104922653A (zh) 治疗或预防哺乳动物对象中骨骼肌衰弱的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
CN105407906A (zh) 预防或治疗巴斯综合征的方法和组合物
CA2916497A1 (en) Methods for the regulation of matrix metalloproteinase expression
HK1176561A (en) Methods for the prevention or treatment of heart failure
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
CA3122262A1 (en) Methods and compositions for the treatment of sengers syndrome
HK1222794B (en) Methods for the prevention or treatment of left ventricle remodeling

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176561

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121003